Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 227 articles:
HTML format
Text format



Single Articles


    October 2018
  1. SHETTY SS, Vishal Rao US
    Changing sexual practices: A possible link to oral cancer.
    Oral Oncol. 2018 Oct 10. pii: S1368-8375(18)30356.
    PubMed     Text format    


  2. LI PJ, Mo HY, Luo DH, Hu WH, et al
    The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Oral Oncol. 2018;85:95-100.
    PubMed     Text format     Abstract available


  3. AMBATIPUDI S, Langdon R, Richmond RC, Suderman M, et al
    DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
    Oral Oncol. 2018;85:87-94.
    PubMed     Text format     Abstract available


  4. LU L, Sheng Y, Zhang G, Li Y, et al
    Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients.
    Oral Oncol. 2018;85:8-14.
    PubMed     Text format     Abstract available


  5. SAKA HERRAN C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J, et al
    Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
    Oral Oncol. 2018;85:68-81.
    PubMed     Text format     Abstract available


  6. CHEN JJ, Harris JP, Kong CS, Sunwoo JB, et al
    Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis.
    Oral Oncol. 2018;85:60-67.
    PubMed     Text format     Abstract available


  7. LEE DJ, Eun YG, Rho YS, Kim EH, et al
    Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Oral Oncol. 2018;85:44-51.
    PubMed     Text format     Abstract available


  8. LIN DJ, McConkey CC, Nankivell P, Dunn J, et al
    The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England.
    Oral Oncol. 2018;85:40-43.
    PubMed     Text format     Abstract available


  9. SRIDHARAN V, Rahman RM, Huang RY, Chau NG, et al
    Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2018;85:29-34.
    PubMed     Text format     Abstract available


    September 2018
  10. MORAND GB, Helmchen BM, Steinert HC, Schmid C, et al
    18F-Choline-PET in parathyroid carcinoma.
    Oral Oncol. 2018 Sep 28. pii: S1368-8375(18)30324.
    PubMed     Text format    


  11. PANTA P
    'Meditation Training Intervention' - A necessary shift for head and neck cancer patients.
    Oral Oncol. 2018 Sep 8. pii: S1368-8375(18)30316.
    PubMed     Text format    


  12. SALOURA V, Vougiouklakis T, Burkitt K, Nakamura Y, et al
    Corrigendum to "The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck" [Oral Oncol. 81 (2018) 100-108].
    Oral Oncol. 2018 Sep 7. pii: S1368-8375(18)30313.
    PubMed     Text format    


  13. DRONKERS EAC, Hoesseini A, de Boer MF, Offerman MPJ, et al
    Communication of prognosis in head and neck cancer patients; a descriptive qualitative analysis.
    Oral Oncol. 2018;84:76-81.
    PubMed     Text format     Abstract available


  14. CHEN MM, Colevas AD, Megwalu U, Divi V, et al
    Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Oral Oncol. 2018;84:71-75.
    PubMed     Text format     Abstract available


  15. FARQUHAR DR, Tanner AM, Masood MM, Patel SR, et al
    Oral tongue carcinoma among young patients: An analysis of risk factors and survival.
    Oral Oncol. 2018;84:7-11.
    PubMed     Text format     Abstract available


  16. WEISS J, Gilbert J, Deal AM, Weissler M, et al
    Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;84:46-51.
    PubMed     Text format     Abstract available


  17. PARK SY, Kim HI, Choi JY, Choe JH, et al
    Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
    Oral Oncol. 2018;84:41-45.
    PubMed     Text format     Abstract available


  18. PENG LC, Hui X, Cheng Z, Bowers MR, et al
    Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients.
    Oral Oncol. 2018;84:25-30.
    PubMed     Text format     Abstract available


  19. STOKES WA, Eguchi M, Amini A, Hararah MK, et al
    Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
    Oral Oncol. 2018;84:12-19.
    PubMed     Text format     Abstract available


  20. LALA M, Chirovsky D, Cheng JD, Mayawala K, et al
    Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Oral Oncol. 2018;84:108-120.
    PubMed     Text format     Abstract available


  21. LI Y, Xu T, Qian W, Lu X, et al
    Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
    Oral Oncol. 2018;84:1-6.
    PubMed     Text format     Abstract available


    August 2018
  22. ANGELIDAKIS G, Sturgis EM, Economides MP, Jiang Y, et al
    Chronic hepatitis C virus infection on patients with nonoropharyngeal head and neck cancers.
    Oral Oncol. 2018 Aug 25. pii: S1368-8375(18)30303.
    PubMed     Text format    


  23. PATTERSON JM, McColl E, Carding PN, Wilson JA, et al
    Swallowing beyond six years post (chemo)radiotherapy for head and neck cancer; a cohort study.
    Oral Oncol. 2018;83:53-58.
    PubMed     Text format     Abstract available


  24. CHOI N, Park SI, Kim H, Sohn I, et al
    The impact of unplanned reoperations in head and neck cancer surgery on survival.
    Oral Oncol. 2018;83:38-45.
    PubMed     Text format     Abstract available


  25. LECHNER M, Chakravarthy AR, Walter V, Masterson L, et al
    Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
    Oral Oncol. 2018;83:32-37.
    PubMed     Text format     Abstract available


  26. MELISSANT HC, Jansen F, Schutte LER, Lissenberg-Witte BI, et al
    The course of sexual interest and enjoyment in head and neck cancer patients treated with primary (chemo)radiotherapy.
    Oral Oncol. 2018;83:120-126.
    PubMed     Text format     Abstract available


  27. HICKS DF, Bakst R, Doucette J, Kann BH, et al
    Impact of obesity on outcomes for patients with head and neck cancer.
    Oral Oncol. 2018;83:11-17.
    PubMed     Text format     Abstract available


  28. ESKANDER A, Krzyzanowska MK, Fischer HD, Liu N, et al
    Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis.
    Oral Oncol. 2018;83:107-114.
    PubMed     Text format     Abstract available


  29. WILKIE MD, Lau AS, Vlatkovic N, Jones TM, et al
    Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
    Oral Oncol. 2018;83:1-10.
    PubMed     Text format     Abstract available


    July 2018
  30. DE BREE R, de Keizer B
    Is there a place for FDG-PET-CT in early oral cancer patients?
    Oral Oncol. 2018 Jul 31. pii: S1368-8375(18)30276.
    PubMed     Text format    


  31. FERRAROTTO R, William WN Jr, Tseng JE, Marur S, et al
    Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:83-90.
    PubMed     Text format     Abstract available


  32. RETTIG EM, Bishop JA, Agrawal N, Chung CH, et al
    HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:168-175.
    PubMed     Text format     Abstract available


  33. HOROWITZ G, Hosni A, Yu E, Xu W, et al
    Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma.
    Oral Oncol. 2018;82:162-167.
    PubMed     Text format     Abstract available


  34. SIANO M, Espeli V, Mach N, Bossi P, et al
    Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.
    Oral Oncol. 2018;82:144-151.
    PubMed     Text format     Abstract available


  35. MASSA ST, Rohde RL, Mckinstry C, Gresham M, et al
    An assessment of patient burdens from head and neck cancer survivorship care.
    Oral Oncol. 2018;82:115-121.
    PubMed     Text format     Abstract available


  36. PENG YL, Chen L, Shen GZ, Li YN, et al
    Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma.
    Oral Oncol. 2018;82:1-7.
    PubMed     Text format     Abstract available


    June 2018
  37. MAIR MD, Shetty R, Nair D, Mathur Y, et al
    Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases.
    Oral Oncol. 2018;81:95-99.
    PubMed     Text format     Abstract available


  38. YUE Q, Zhang M, Chen Y, Zheng D, et al
    Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: A meta-analysis.
    Oral Oncol. 2018;81:81-88.
    PubMed     Text format     Abstract available


  39. MOTT FE, Ferrarotto R, Nguyen T, Phan J, et al
    Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy.
    Oral Oncol. 2018;81:75-80.
    PubMed     Text format     Abstract available


  40. RASMUSSEN JH, Hakansson K, Rasmussen GB, Vogelius IR, et al
    A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients.
    Oral Oncol. 2018;81:52-60.
    PubMed     Text format     Abstract available


  41. FERRIS RL, Blumenschein G Jr, Fayette J, Guigay J, et al
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol. 2018;81:45-51.
    PubMed     Text format     Abstract available


  42. OSAZUWA-PETERS N, Arnold LD, Loux TM, Varvares MA, et al
    Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis.
    Oral Oncol. 2018;81:29-34.
    PubMed     Text format     Abstract available


  43. KRAEIMA J, Dorgelo B, Gulbitti HA, Steenbakkers RJHM, et al
    Multi-modality 3D mandibular resection planning in head and neck cancer using CT and MRI data fusion: A clinical series.
    Oral Oncol. 2018;81:22-28.
    PubMed     Text format     Abstract available


  44. LIN MC, Shueng PW, Chang WK, Mu-Hsin Chang P, et al
    Consensus and clinical recommendations for nutritional intervention for head and neck cancer patients undergoing chemoradiotherapy in Taiwan.
    Oral Oncol. 2018;81:16-21.
    PubMed     Text format     Abstract available


  45. SALOURA V, Vougiouklakis T, Sievers C, Burkitt K, et al
    The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;81:100-108.
    PubMed     Text format     Abstract available


  46. HANNA GJ, Kofman ER, Shazib MA, Woo SB, et al
    Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
    Oral Oncol. 2018;81:1-9.
    PubMed     Text format     Abstract available


    May 2018
  47. CARPENTER DJ, Mowery YM, Broadwater G, Rodrigues A, et al
    The risk of carotid stenosis in head and neck cancer patients after radiation therapy.
    Oral Oncol. 2018;80:9-15.
    PubMed     Text format     Abstract available


  48. BASHEER HA, Pakanavicius E, Cooper PA, Shnyder SD, et al
    Hypoxia modulates CCR7 expression in head and neck cancers.
    Oral Oncol. 2018;80:64-73.
    PubMed     Text format     Abstract available


  49. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Text format     Abstract available


  50. IOCCA O, Farcomeni A, Di Rocco A, Di Maio P, et al
    Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Oral Oncol. 2018;80:40-51.
    PubMed     Text format     Abstract available


  51. HANEMAAIJER SH, van Gijn SE, Oosting SF, Plaat BEC, et al
    Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;80:33-39.
    PubMed     Text format     Abstract available


  52. LIN M, You R, Liu YP, Zhang YN, et al
    Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2018;80:1-8.
    PubMed     Text format     Abstract available


    April 2018
  53. TARDY MP, Di Mauro I, Ebran N, Refae S, et al
    Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Apr 6. pii: S1368-8375(18)30124.
    PubMed     Text format    


  54. GARCIA-ESCUDERO R, Segrelles C, Duenas M, Pombo M, et al
    Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    Oral Oncol. 2018;79:55-63.
    PubMed     Text format     Abstract available


  55. PENG H, Tang LL, Chen BB, Chen L, et al
    Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.
    Oral Oncol. 2018;79:40-46.
    PubMed     Text format     Abstract available


  56. CAO C, Jiang F, Jin Q, Jin T, et al
    Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension.
    Oral Oncol. 2018;79:27-32.
    PubMed     Text format     Abstract available


  57. VAISANEN JA, Alho OP, Koivunen PT, Laara E, et al
    Cause-specific mortality in patients with head and neck cancer: Long-term follow-up of a population-based cohort from 1986 to 2012 accounting for competing risks.
    Oral Oncol. 2018;79:20-26.
    PubMed     Text format     Abstract available


  58. KAMAL M, Ng SP, Eraj SA, Rock CD, et al
    Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.
    Oral Oncol. 2018;79:1-8.
    PubMed     Text format     Abstract available


    March 2018
  59. GUPTA AA, Pande N, Kheur S, Raj AT, et al
    Assessing the potential role of scaffold-mediated local chemotherapy in oral cancer.
    Oral Oncol. 2018 Mar 16. pii: S1368-8375(18)30111.
    PubMed     Text format    


  60. MIZRACHI A, Migliacci JC, Montero PH, McBride S, et al
    Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution.
    Oral Oncol. 2018;78:94-101.
    PubMed     Text format     Abstract available


  61. HAN MW, Ryu IS, Lee JC, Kim SH, et al
    Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
    Oral Oncol. 2018;78:56-63.
    PubMed     Text format     Abstract available


  62. CHAN JYW, Wong STS, Wei WI
    Real time indocyanin green near infrared lymphangiography for the reduction of drainage volume after neck dissection.
    Oral Oncol. 2018;78:52-55.
    PubMed     Text format     Abstract available


  63. XU C, Sun R, Tang LL, Chen L, et al
    Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Oral Oncol. 2018;78:37-45.
    PubMed     Text format     Abstract available


  64. LU S, Concha-Benavente F, Shayan G, Srivastava RM, et al
    STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.
    Oral Oncol. 2018;78:186-193.
    PubMed     Text format     Abstract available


  65. PARK YP, Jin L, Bennett KB, Wang D, et al
    CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;78:145-150.
    PubMed     Text format     Abstract available


  66. RETZBACH EP, Sheehan SA, Nevel EM, Batra A, et al
    Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
    Oral Oncol. 2018;78:126-136.
    PubMed     Text format     Abstract available


  67. BRANDAO NETO JS, Aires FT, Dedivitis RA, Matos LL, et al
    Comparison between magnetic resonance and computed tomography in detecting mandibular invasion in oral cancer: A systematic review and diagnostic meta-analysis: MRI x CT in mandibular invasion.
    Oral Oncol. 2018;78:114-118.
    PubMed     Text format     Abstract available


  68. SLOOTER MD, Handgraaf HJM, Boonstra MC, van der Velden LA, et al
    Detecting tumour-positive resection margins after oral cancer surgery by spraying a fluorescent tracer activated by gamma-glutamyltranspeptidase.
    Oral Oncol. 2018;78:1-7.
    PubMed     Text format     Abstract available


    February 2018
  69. MUMTAZ S, Parrish J, Singh M
    Oculosympathetic paresis after selective neck dissection: A 'distant' complication.
    Oral Oncol. 2018 Feb 16. pii: S1368-8375(18)30042.
    PubMed     Text format    


  70. GOPINATH D, Menon RK
    Comments on "Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer" by Yang et al.
    Oral Oncol. 2018 Feb 10. pii: S1368-8375(18)30052.
    PubMed     Text format    


  71. PAI SI, Jack Lee J, Carey TE, Westra WH, et al
    HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Oral Oncol. 2018;77:92-97.
    PubMed     Text format     Abstract available


  72. GIPSON BJ, Robbins HA, Fakhry C, D'Souza G, et al
    Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.
    Oral Oncol. 2018;77:52-56.
    PubMed     Text format     Abstract available


  73. HUO M, Panizza B, Bernard A, Porceddu SV, et al
    Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer.
    Oral Oncol. 2018;77:43-48.
    PubMed     Text format     Abstract available


  74. MAJERCAKOVA K, Valero C, Lopez M, Garcia J, et al
    Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients.
    Oral Oncol. 2018;77:37-42.
    PubMed     Text format     Abstract available


  75. KLEIN NULENT TJW, Noorlag R, Van Cann EM, Pameijer FA, et al
    Intraoral ultrasonography to measure tumor thickness of oral cancer: A systematic review and meta-analysis.
    Oral Oncol. 2018;77:29-36.
    PubMed     Text format     Abstract available


  76. AU KH, Ngan RKC, Ng AWY, Poon DMC, et al
    Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Oral Oncol. 2018;77:16-21.
    PubMed     Text format     Abstract available


  77. VAN DEN BOVENKAMP K, Dorgelo B, Noordhuis MG, van der Laan BFAM, et al
    Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.
    Oral Oncol. 2018;77:131-136.
    PubMed     Text format     Abstract available


  78. DE FELICE F, de Vincentiis M, Luzzi V, Magliulo G, et al
    Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management.
    Oral Oncol. 2018;77:125-130.
    PubMed     Text format     Abstract available


  79. YANG SF, Huang HD, Fan WL, Jong YJ, et al
    Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer.
    Oral Oncol. 2018;77:1-8.
    PubMed     Text format     Abstract available


    January 2018
  80. WANG Y, Qin X, Zhu X, Chen W, et al
    Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41].
    Oral Oncol. 2018 Jan 25. pii: S1368-8375(18)30015.
    PubMed     Text format    


  81. XU T, Zhou X, Shen C, Hu C, et al
    Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: Based on hazard-rate and patterns of recurrence.
    Oral Oncol. 2018;76:61-67.
    PubMed     Text format     Abstract available


  82. SZTURZ P, Wouters K, Kiyota N, Tahara M, et al
    Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.
    Oral Oncol. 2018;76:52-60.
    PubMed     Text format     Abstract available


  83. KUFTA K, Forman M, Swisher-McClure S, Sollecito TP, et al
    Pre-Radiation dental considerations and management for head and neck cancer patients.
    Oral Oncol. 2018;76:42-51.
    PubMed     Text format     Abstract available


  84. WANG Y, Qin X, Zhu X, Chen W, et al
    Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway.
    Oral Oncol. 2018;76:34-41.
    PubMed     Text format     Abstract available


  85. MARCAZZAN S, Varoni EM, Blanco E, Lodi G, et al
    Nanomedicine, an emerging therapeutic strategy for oral cancer therapy.
    Oral Oncol. 2018;76:1-7.
    PubMed     Text format     Abstract available


    December 2017
  86. VARELA-CENTELLES P, Garcia-Martin JM, Seoane-Romero J
    On the studies of time periods in head and neck cancer diagnosis and treatment.
    Oral Oncol. 2017 Dec 27. pii: S1368-8375(17)30415.
    PubMed     Text format    


  87. PENG H, Chen BB, Chen L, Chen YP, et al
    A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy.
    Oral Oncol. 2017;75:89-94.
    PubMed     Text format     Abstract available


  88. VAN GINKEL JH, Slieker FJB, de Bree R, van Es RJJ, et al
    Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature.
    Oral Oncol. 2017;75:8-15.
    PubMed     Text format     Abstract available


  89. KULASINGHE A, Kenny L, Punyadeera C
    Circulating tumour cell PD-L1 test for head and neck cancers.
    Oral Oncol. 2017;75:6-7.
    PubMed     Text format     Abstract available


  90. JOSHI A, Patil V, Noronha V, Dhumal S, et al
    Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2017;75:54-60.
    PubMed     Text format     Abstract available


  91. CHENG SJ, Chang CF, Ko HH, Liu YC, et al
    Hypermethylated ZNF582 and PAX1 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer.
    Oral Oncol. 2017;75:169-177.
    PubMed     Text format     Abstract available


  92. CHHABRIA KS, Carnaby GD
    Psychometric validation of the Center for Epidemiological Studies Depression Scale in Head and Neck Cancer patients.
    Oral Oncol. 2017;75:158-162.
    PubMed     Text format     Abstract available


  93. LI WF, Zhang Y, Liu X, Tang LL, et al
    Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;75:120-126.
    PubMed     Text format     Abstract available


  94. ASHIZAWA K, Yoshimura K, Johno H, Inoue T, et al
    Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma.
    Oral Oncol. 2017;75:111-119.
    PubMed     Text format     Abstract available


  95. KANG M, Zhou P, Liao X, Xu M, et al
    Prognostic value of masticatory muscle involvement in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Oral Oncol. 2017;75:100-105.
    PubMed     Text format     Abstract available


  96. PARK YM, Lee DY, Oh KH, Cho JG, et al
    Clinical implications of pathologic factors after thyroid lobectomy in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017;75:1-5.
    PubMed     Text format     Abstract available


    November 2017
  97. RAJ AT, Patil S, Sarode SC, Sarode GS, et al
    Evaluating the association between household air pollution and oral cancer.
    Oral Oncol. 2017 Nov 11. pii: S1368-8375(17)30363.
    PubMed     Text format    


  98. ECONOMOPOULOU P, Kotsantis I, Kyrodimos E, Lianidou ES, et al
    Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
    Oral Oncol. 2017;74:83-89.
    PubMed     Text format     Abstract available


  99. FADEN DL, Thomas S, Cantalupo PG, Agrawal N, et al
    Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;74:8-14.
    PubMed     Text format     Abstract available


  100. HAKANSSON K, Rasmussen JH, Rasmussen GB, Friborg J, et al
    A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments.
    Oral Oncol. 2017;74:77-82.
    PubMed     Text format     Abstract available


  101. SZTURZ P, Budikova M, Vermorken JB, Horova I, et al
    Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.
    Oral Oncol. 2017;74:68-76.
    PubMed     Text format     Abstract available


  102. WARD MC, Shah C, Adelstein DJ, Geiger JL, et al
    Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer.
    Oral Oncol. 2017;74:49-55.
    PubMed     Text format     Abstract available


  103. MI JL, Zhang B, Pan YF, Su YX, et al
    Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
    Oral Oncol. 2017;74:34-39.
    PubMed     Text format     Abstract available


  104. DIRVEN R, Ebrahimi A, Moeckelmann N, Palme CE, et al
    Tumor thickness versus depth of invasion - Analysis of the 8th edition American Joint Committee on Cancer Staging for oral cancer.
    Oral Oncol. 2017;74:30-33.
    PubMed     Text format     Abstract available


  105. AJMANI GS, Nocon CC, Wang CH, Bhayani MK, et al
    Assessment of adjuvant therapy in resected head and neck cancer with high-risk features.
    Oral Oncol. 2017;74:15-20.
    PubMed     Text format     Abstract available


  106. TAO Y, Gross N, Liu Y, Zhang L, et al
    A high ratio of IL-12Rbeta2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer.
    Oral Oncol. 2017;74:148-156.
    PubMed     Text format     Abstract available


  107. BONOMO P, Desideri I, Loi M, Lo Russo M, et al
    Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?
    Oral Oncol. 2017;74:142-147.
    PubMed     Text format     Abstract available


  108. PAPAKOSTAS P, Tsaousi G, Stavrou G, Rachovitsas D, et al
    Percutaneous endoscopic gastrostomy feeding of locally advanced oro-pharygo-laryngeal cancer patients: Blenderized or commercial food?
    Oral Oncol. 2017;74:135-141.
    PubMed     Text format     Abstract available


  109. SU TL, Chen AN, Leong CP, Huang YC, et al
    The effect of home-based program and outpatient physical therapy in patients with head and neck cancer: A randomized, controlled trial.
    Oral Oncol. 2017;74:130-134.
    PubMed     Text format     Abstract available


  110. PATINO MA, Ramirez RE, Perez CA, Feng L, et al
    The impact of intraoperative opioid use on survival after oral cancer surgery.
    Oral Oncol. 2017;74:1-7.
    PubMed     Text format     Abstract available


    October 2017
  111. WU M, Ou D, He X, Hu C, et al
    Corrigendum to "Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma" [Oral Oncol. 73 (2017) 118-123].
    Oral Oncol. 2017 Oct 11. pii: S1368-8375(17)30306.
    PubMed     Text format     Abstract available


  112. LI YC, Chen FP, Zhou GQ, Zhu JH, et al
    Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:97-104.
    PubMed     Text format     Abstract available


  113. TSAI MS, Chen WC, Lai CH, Chen YY, et al
    Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer.
    Oral Oncol. 2017;73:88-96.
    PubMed     Text format     Abstract available


  114. WU SG, Liao XL, He ZY, Tang LY, et al
    Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis.
    Oral Oncol. 2017;73:83-87.
    PubMed     Text format     Abstract available


  115. HANNA GJ, Adkins DR, Zolkind P, Uppaluri R, et al
    Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;73:65-69.
    PubMed     Text format     Abstract available


  116. NAKANO K, Marshall S, Taira S, Sato Y, et al
    A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Oral Oncol. 2017;73:21-26.
    PubMed     Text format     Abstract available


  117. KIYOTA N, Hasegawa Y, Takahashi S, Yokota T, et al
    A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
    Oral Oncol. 2017;73:138-146.
    PubMed     Text format     Abstract available


  118. WU M, Ou D, He X, Hu C, et al
    Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:118-123.
    PubMed     Text format    


  119. FARQUHAR DR, Divaris K, Mazul AL, Weissler MC, et al
    Poor oral health affects survival in head and neck cancer.
    Oral Oncol. 2017;73:111-117.
    PubMed     Text format     Abstract available


  120. HUANG SF, Hsiao JH, Young CK, Chien HT, et al
    Familial aggregation of nasopharyngeal carcinoma in Taiwan.
    Oral Oncol. 2017;73:10-15.
    PubMed     Text format     Abstract available


  121. UPADHYAY P, Gardi N, Desai S, Chandrani P, et al
    Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 asa candidate to predict metastases.
    Oral Oncol. 2017;73:56-64.
    PubMed     Text format     Abstract available


  122. SHARMA SJ, Wittekindt C, Knuth J, Steiner D, et al
    Intraindividual homogeneity of 18F-FDG PET/CT parameters in HPV-positive OPSCC.
    Oral Oncol. 2017;73:166-171.
    PubMed     Text format     Abstract available


  123. ZHAN KY, Eskander A, Kang SY, Old MO, et al
    Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.
    Oral Oncol. 2017;73:152-159.
    PubMed     Text format     Abstract available


    September 2017
  124. VEVE MP, Davis SL, Williams AM, McKinnon JE, et al
    Considerations for antibiotic prophylaxis in head and neck cancer surgery.
    Oral Oncol. 2017 Sep 21. pii: S1368-8375(17)30281.
    PubMed     Text format     Abstract available


  125. SAHOVALER A, Yeh D, Yoo J
    Primary facial reanimation in head and neck cancer.
    Oral Oncol. 2017 Sep 12. pii: S1368-8375(17)30246.
    PubMed     Text format     Abstract available


  126. OUYANG PY, Xiao Y, You KY, Zhang LN, et al
    Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi.
    Oral Oncol. 2017;72:65-72.
    PubMed     Text format     Abstract available


  127. KRISHNAN AR, Zheng H, Kwok JG, Qu Y, et al
    A comprehensive study of smoking-specific microRNA alterations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:56-64.
    PubMed     Text format     Abstract available


  128. LI K, Yang L, Xin P, Chen Y, et al
    Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy.
    Oral Oncol. 2017;72:32-37.
    PubMed     Text format     Abstract available


  129. ADKINS D, Ley J, Oppelt P, Wildes TM, et al
    nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:26-31.
    PubMed     Text format     Abstract available


  130. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.
    Oral Oncol. 2017;72:17-25.
    PubMed     Text format     Abstract available


  131. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.
    Oral Oncol. 2017;72:140-149.
    PubMed     Text format     Abstract available


  132. ALEXANDER-BRYANT AA, Zhang H, Attaway CC, Pugh W, et al
    Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
    Oral Oncol. 2017;72:123-131.
    PubMed     Text format     Abstract available


  133. STOKES WA, Stumpf PK, Jones BL, Blatchford PJ, et al
    Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States.
    Oral Oncol. 2017;72:110-116.
    PubMed     Text format     Abstract available


  134. ALSIDAWI S, Price KA, Chintakuntlawar AV, Westin GF, et al
    Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation.
    Oral Oncol. 2017;72:104-109.
    PubMed     Text format     Abstract available


  135. DONA MG, Rollo F, Pichi B, Spriano G, et al
    Evaluation of the Xpert(R) HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas.
    Oral Oncol. 2017;72:117-122.
    PubMed     Text format     Abstract available


    August 2017
  136. SAFIRI S, Ayubi E
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease: Methodological issues.
    Oral Oncol. 2017;71:95.
    PubMed     Text format    


  137. MORISADA M, Moore EC, Hodge R, Friedman J, et al
    Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.
    Oral Oncol. 2017;71:87-94.
    PubMed     Text format     Abstract available


  138. KIM TH, Kim YN, Kim HI, Park SY, et al
    Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.
    Oral Oncol. 2017;71:81-86.
    PubMed     Text format     Abstract available


  139. ARRIBAS L, Hurtos L, Taberna M, Peiro I, et al
    Nutritional changes in patients with locally advanced head and neck cancer during treatment.
    Oral Oncol. 2017;71:67-74.
    PubMed     Text format     Abstract available


  140. TAO Y, Auperin A, Graff P, Lapeyre M, et al
    Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Oral Oncol. 2017;71:61-66.
    PubMed     Text format     Abstract available


  141. KITANI Y, Kubota A, Furukawa M, Hori Y, et al
    Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
    Oral Oncol. 2017;71:54-59.
    PubMed     Text format     Abstract available


  142. MATOS LL, Dedivitis RA, Kulcsar MAV, de Mello ES, et al
    External validation of the AJCC Cancer Staging Manual, 8th edition, in an independent cohort of oral cancer patients.
    Oral Oncol. 2017;71:47-53.
    PubMed     Text format     Abstract available


  143. MASSA ST, Osazuwa-Peters N, Franco J, Ward GW, et al
    Survival after refusal of surgical treatment for locally advanced laryngeal cancer.
    Oral Oncol. 2017;71:34-40.
    PubMed     Text format     Abstract available


  144. WENDRICH AW, Swartz JE, Bril SI, Wegner I, et al
    Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Oral Oncol. 2017;71:26-33.
    PubMed     Text format     Abstract available


  145. OOFT ML, van Ipenburg JA, Braunius WW, Zuur CI, et al
    Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma.
    Oral Oncol. 2017;71:16-25.
    PubMed     Text format     Abstract available


  146. HINGORANI DV, Lemieux AJ, Acevedo JR, Glasgow HL, et al
    Early detection of squamous cell carcinoma in carcinogen induced oral cancer rodent model by ratiometric activatable cell penetrating peptides.
    Oral Oncol. 2017;71:156-162.
    PubMed     Text format     Abstract available


  147. OU D, Blanchard P, Rosellini S, Levy A, et al
    Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Oral Oncol. 2017;71:150-155.
    PubMed     Text format     Abstract available


  148. BRYERE J, Menvielle G, Dejardin O, Launay L, et al
    Neighborhood deprivation and risk of head and neck cancer: A multilevel analysis from France.
    Oral Oncol. 2017;71:144-149.
    PubMed     Text format     Abstract available


  149. PARK YM, Jung CM, Cha D, Kim SH, et al
    The long-term oncological and functional outcomes of transoral robotic surgery in patients with hypopharyngeal cancer.
    Oral Oncol. 2017;71:138-143.
    PubMed     Text format     Abstract available


  150. DONG Y, Ridge JA, Li T, Lango MN, et al
    Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer.
    Oral Oncol. 2017;71:122-128.
    PubMed     Text format     Abstract available


  151. GIULIANI M, Milne R, McQuestion M, Sampson L, et al
    Partner's survivorship care needs: An analysis in head and neck cancer patients.
    Oral Oncol. 2017;71:113-121.
    PubMed     Text format     Abstract available


  152. ANTUNES HS, Herchenhorn D, Small IA, Araujo CMM, et al
    Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis.
    Oral Oncol. 2017;71:11-15.
    PubMed     Text format     Abstract available


  153. CHEN MM, Orosco RK, Harris JP, Porter JB, et al
    Predictors of readmissions after head and neck cancer surgery: A national perspective.
    Oral Oncol. 2017;71:106-112.
    PubMed     Text format     Abstract available


  154. JERZAK KJ, Delos Santos K, Saluja R, Lien K, et al
    A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).
    Oral Oncol. 2017;71:1-10.
    PubMed     Text format     Abstract available


    July 2017
  155. BAIS MV, Kukuruzinska M, Trackman PC
    Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482].
    Oral Oncol. 2017 Jul 22. pii: S1368-8375(17)30198.
    PubMed     Text format    


  156. CHAN JYW, Chan RCL, Chow VLY, Tsang RKY, et al
    Transoral robotic total laryngopharyngectomy and free jejunal flap reconstruction for hypopharyngeal cancer.
    Oral Oncol. 2017 Jul 15. pii: S1368-8375(17)30187.
    PubMed     Text format     Abstract available


  157. KE LR, Xia WX, Qiu WZ, Huang XJ, et al
    A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;70:7-13.
    PubMed     Text format     Abstract available


  158. JI YB, Song CM, Bang HS, Park HJ, et al
    Functional and cosmetic outcomes of robot-assisted neck dissection by a postauricular facelift approach for head and neck cancer.
    Oral Oncol. 2017;70:51-57.
    PubMed     Text format     Abstract available


  159. DE MEULENAERE A, Vermassen T, Aspeslagh S, Huvenne W, et al
    Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;70:34-42.
    PubMed     Text format     Abstract available


  160. ALI J, Sabiha B, Jan HU, Haider SA, et al
    Genetic etiology of oral cancer.
    Oral Oncol. 2017;70:23-28.
    PubMed     Text format     Abstract available


  161. BROGLIE MA, Jochum W, Michel A, Waterboer T, et al
    Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.
    Oral Oncol. 2017;70:43-50.
    PubMed     Text format     Abstract available


    June 2017
  162. LE QT, Welch JJ, Vermorken JB, Rischin D, et al
    Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG.
    Oral Oncol. 2017 Jun 22. pii: S1368-8375(17)30139.
    PubMed     Text format     Abstract available


  163. XU C, Chen YP, Liu X, Li WF, et al
    Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Oral Oncol. 2017;69:99-107.
    PubMed     Text format     Abstract available


  164. AI QY, King AD, Mo FKF, Law BKH, et al
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease.
    Oral Oncol. 2017;69:74-79.
    PubMed     Text format     Abstract available


  165. TANG LL, Tang XR, Li WF, Chen L, et al
    The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.
    Oral Oncol. 2017;69:68-73.
    PubMed     Text format     Abstract available


  166. ADAMI GR, Tang JL, Markiewicz MR
    Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.
    Oral Oncol. 2017;69:62-67.
    PubMed     Text format     Abstract available


  167. LAPRISE C, Madathil SA, Schlecht NF, Castonguay G, et al
    Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.
    Oral Oncol. 2017;69:56-61.
    PubMed     Text format     Abstract available


  168. STABILE LP, Egloff AM, Gibson MK, Gooding WE, et al
    IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
    Oral Oncol. 2017;69:38-45.
    PubMed     Text format     Abstract available


  169. WU LR, Liu YT, Jiang N, Fan YX, et al
    Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center.
    Oral Oncol. 2017;69:26-32.
    PubMed     Text format     Abstract available


  170. WICHMANN G, Herchenhahn C, Boehm A, Mozet C, et al
    HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
    Oral Oncol. 2017;69:115-127.
    PubMed     Text format     Abstract available


  171. CHEN CC, Lin JC, Chen KW
    Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
    Oral Oncol. 2017;69:11-14.
    PubMed     Text format     Abstract available


  172. DABAS S, Gupta K, Ranjan R, Sharma AK, et al
    Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial.
    Oral Oncol. 2017;69:80-83.
    PubMed     Text format     Abstract available


    May 2017
  173. CHOUGULE A, Patil VM, Noronha V, Joshi A, et al
    Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
    Oral Oncol. 2017 May 22. pii: S1368-8375(17)30115.
    PubMed     Text format    


  174. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Text format     Abstract available


  175. NOIJ DP, Martens RM, Marcus JT, de Bree R, et al
    Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value.
    Oral Oncol. 2017;68:81-91.
    PubMed     Text format     Abstract available


  176. ZHAI RP, Kong FF, Du CR, Hu CS, et al
    Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
    Oral Oncol. 2017;68:44-49.
    PubMed     Text format     Abstract available


  177. HUANG TT, Huang JS, Wang YY, Chen KC, et al
    Novel quantitative analysis of autofluorescence images for oral cancer screening.
    Oral Oncol. 2017;68:20-26.
    PubMed     Text format     Abstract available


  178. DODD RH, Forster AS, Waller J, Marlow LAV, et al
    Discussing HPV with oropharyngeal cancer patients: A cross-sectional survey of attitudes in health professionals.
    Oral Oncol. 2017;68:67-73.
    PubMed     Text format     Abstract available


    April 2017
  179. RUEDA A, Giralt J, Manos M, Lozano A, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30087.
    PubMed     Text format     Abstract available


  180. MANOS M, Giralt J, Rueda A, Cabrera J, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30088.
    PubMed     Text format     Abstract available


  181. AYUBI E, Safiri S
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity.
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30086.
    PubMed     Text format    


  182. YANG Q, Zou X, You R, Liu YP, et al
    Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis.
    Oral Oncol. 2017;67:83-88.
    PubMed     Text format     Abstract available


  183. BORCHIELLINI D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, et al
    Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
    Oral Oncol. 2017;67:70-76.
    PubMed     Text format     Abstract available


  184. HANNA GJ, Liu H, Jones RE, Bacay AF, et al
    Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:61-69.
    PubMed     Text format     Abstract available


  185. OUYANG PY, Zhang LN, Xiao Y, Lan XW, et al
    Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;67:37-45.
    PubMed     Text format     Abstract available


  186. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Text format     Abstract available


  187. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:183-191.
    PubMed     Text format     Abstract available


  188. POLESEL J, Furlan C, Birri S, Giacomarra V, et al
    The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy.
    Oral Oncol. 2017;67:175-182.
    PubMed     Text format     Abstract available


  189. XIA WX, Liang H, Lv X, Wang L, et al
    Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
    Oral Oncol. 2017;67:167-174.
    PubMed     Text format     Abstract available


  190. CHAU L, Jabara JT, Lai W, Svider PF, et al
    Topical agents for oral cancer chemoprevention: A systematic review of the literature.
    Oral Oncol. 2017;67:153-159.
    PubMed     Text format     Abstract available


  191. DE FELICE F, Guerrero Urbano T
    New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
    Oral Oncol. 2017;67:119-123.
    PubMed     Text format     Abstract available


  192. KADLETZ L, Thurnher D, Wiebringhaus R, Erovic BM, et al
    Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:109-118.
    PubMed     Text format     Abstract available


  193. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Text format     Abstract available


  194. RASTOGI M, Sapru S, Gupta P, Gandhi AK, et al
    Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
    Oral Oncol. 2017;67:10-16.
    PubMed     Text format     Abstract available


  195. HAMOIR M, Holvoet E, Ambroise J, Lengele B, et al
    Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.
    Oral Oncol. 2017;67:1-9.
    PubMed     Text format     Abstract available


  196. LIAO CT, Wen YW, Yang LY, Lee SR, et al
    Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas.
    Oral Oncol. 2017;67:95-102.
    PubMed     Text format     Abstract available


  197. LEVI S, Zini A, Fischman S, Czerninski R, et al
    Epidemiology of oral, salivary gland and pharyngeal cancer in children and adolescents between 1970 and 2011.
    Oral Oncol. 2017;67:89-94.
    PubMed     Text format     Abstract available


  198. ZHANG Y, Waterboer T, Haddad RI, Miles BA, et al
    Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
    Oral Oncol. 2017;67:77-82.
    PubMed     Text format     Abstract available


  199. CHAN OS, Kowanetz M, Ng WT, Koeppen H, et al
    Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
    Oral Oncol. 2017;67:52-60.
    PubMed     Text format     Abstract available


  200. VELEZ MA, Veruttipong D, Wang PC, Chin R, et al
    Re-irradiation for recurrent and second primary cancers of the head and neck.
    Oral Oncol. 2017;67:46-51.
    PubMed     Text format     Abstract available


  201. LACAU ST GUILY J, Rousseau A, Baujat B, Perie S, et al
    Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study.
    Oral Oncol. 2017;67:29-36.
    PubMed     Text format     Abstract available


  202. KATO MG, Erkul E, Brewer KS, Harruff EE, et al
    Clinical features of ectomesenchymal chondromyxoid tumors: A systematic review of the literature.
    Oral Oncol. 2017;67:192-197.
    PubMed     Text format     Abstract available


  203. ALLI N, Meer S
    Head and neck lymphomas: A 20-year review in an Oral Pathology Unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS.
    Oral Oncol. 2017;67:17-23.
    PubMed     Text format     Abstract available


  204. HAY A, Migliacci J, Karassawa Zanoni D, Boyle JO, et al
    Complications following transoral robotic surgery (TORS): A detailed institutional review of complications.
    Oral Oncol. 2017;67:160-166.
    PubMed     Text format     Abstract available


  205. TOTA JE, Anderson WF, Coffey C, Califano J, et al
    Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012.
    Oral Oncol. 2017;67:146-152.
    PubMed     Text format     Abstract available


  206. GISSI DB, Tarsitano A, Leonardi E, Gabusi A, et al
    Clonal analysis as a prognostic factor in multiple oral squamous cell carcinoma.
    Oral Oncol. 2017;67:131-137.
    PubMed     Text format     Abstract available


  207. KARATAS OF, Oner M, Abay A, Diyapoglu A, et al
    MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications.
    Oral Oncol. 2017;67:124-130.
    PubMed     Text format     Abstract available


    March 2017
  208. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Text format     Abstract available


    February 2017
  209. GIRELLI L, Locati L, Galeone C, Scanagatta P, et al
    Lung metastasectomy in adenoid cystic cancer: Is it worth it?
    Oral Oncol. 2017;65:114-118.
    PubMed     Text format     Abstract available


  210. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Text format     Abstract available


  211. VAN GENECHTEN ML, Batstone MD
    The fate of the free flap pedicle after free tissue transfer to the head and neck area.
    Oral Oncol. 2017;65:65-67.
    PubMed     Text format     Abstract available


  212. MERY B, Rancoule C, Guy JB, Espenel S, et al
    Preclinical models in HNSCC: A comprehensive review.
    Oral Oncol. 2017;65:51-56.
    PubMed     Text format     Abstract available


  213. GENTILE MS, Yip D, Liebsch NJ, Adams JA, et al
    Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull.
    Oral Oncol. 2017;65:38-44.
    PubMed     Text format     Abstract available


  214. NARUSE T, Yanamoto S, Okuyama K, Yamashita K, et al
    Therapeutic implication of mTORC2 in oral squamous cell carcinoma.
    Oral Oncol. 2017;65:23-32.
    PubMed     Text format     Abstract available


  215. VASSILIOU LV, Lalabekyan B, Jay A, Liew C, et al
    Head and neck sarcomas: A single institute series.
    Oral Oncol. 2017;65:16-22.
    PubMed     Text format     Abstract available


  216. TAM AA, Ozdemir D, Cuhaci N, Baser H, et al
    Can ratio of the biggest tumor diameter to total tumor diameter be a new parameter in the differential diagnosis of agressive and favorable multifocal papillary thyroid microcarcinoma?
    Oral Oncol. 2017;65:1-7.
    PubMed     Text format     Abstract available


  217. LOMBARDI D, McGurk M, Vander Poorten V, Guzzo M, et al
    Surgical treatment of salivary malignant tumors.
    Oral Oncol. 2017;65:102-113.
    PubMed     Text format     Abstract available


    January 2017
  218. O'HARE J, Maclean J, Szczesniak M, Gupta R, et al
    Laryngeal tumours and radiotherapy dose to the cricopharyngeus are predictive of death from aspiration pneumonia.
    Oral Oncol. 2017;64:9-14.
    PubMed     Text format     Abstract available


  219. SHAW R, Tesfaye B, Bickerstaff M, Silcocks P, et al
    Refining the definition of mandibular osteoradionecrosis in clinical trials: The cancer research UK HOPON trial (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis).
    Oral Oncol. 2017;64:73-77.
    PubMed     Text format     Abstract available


  220. OWOSHO AA, Tsai CJ, Lee RS, Freymiller H, et al
    The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.
    Oral Oncol. 2017;64:44-51.
    PubMed     Text format     Abstract available


  221. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Text format     Abstract available


  222. YAMADA SI, Kurita H, Tomioka T, Ohta R, et al
    Healthy life expectancy of oral squamous cell carcinoma patients aged 75years and older.
    Oral Oncol. 2017;64:22-26.
    PubMed     Text format     Abstract available


    November 2016
  223. HAUGHEY BH, Sinha P, Kallogjeri D, Goldberg RL, et al
    Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.
    Oral Oncol. 2016;62:11-19.
    PubMed     Text format     Abstract available


  224. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Text format     Abstract available


    September 2016
  225. D'SOUZA G, Zhang Y, Merritt S, Gold D, et al
    Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer.
    Oral Oncol. 2016;60:90-5.
    PubMed     Text format     Abstract available


  226. CHATURVEDI AK, D'Souza G, Gillison ML, Katki HA, et al
    Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.
    Oral Oncol. 2016;60:61-7.
    PubMed     Text format     Abstract available


    July 2016
  227. SABER CN, Gronhoj Larsen C, Dalianis T, von Buchwald C, et al
    Immune cells and prognosis in HPV-associated oropharyngeal squamous cell carcinomas: Review of the literature.
    Oral Oncol. 2016;58:8-13.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: